Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 845

Sort by

Sort Order Select

Journal Articles

GATA2 -Dependent Developmental and Regenerative Networks

Alexandra Soukup, PhD, Kirby D Johnson, PhD, Daniel J Conn, PhD, Evgenia Shishkova, PhD, Koichi Ricardo Katsumura, MD PhD, Peng Liu, PhD, Erik A. Ranheim, MD PhD, Katherine R. Calvo, MD PhD, Amy P. Hsu, Steven M. Holland, MD, Joshua J Coon, PhD, Sunduz Keles, PhD, Emery H Bresnick, PhD

Blood (2019) 134 (Supplement_1): 1182.

https://doi.org/10.1182/blood-2019-126875

Published: 2019

Journal Articles

PU.1 Enforces Hematopoietic Stem Cell Quiescence during Chronic Inflammation

James Chavez, BS, Jennifer L Rabe, BS, BA, Kelly Higa, MS, Dirk Loeffler, Ahmed Nouraiz, PhD, Taylor Mills, BA, Beau M Idler, Brett M. Stevens, PhD, Courtney Fleenor, PhD, Claus Nerlov, PhD, Hideaki Nakajima, MD, James Hagman, Timm Schroeder, PhD, Hyun Min Kim, PhD, Craig T Jordan, PhD, James DeGregori, Eric Pietras, PhD

Blood (2019) 134 (Supplement_1): 822.

https://doi.org/10.1182/blood-2019-129300

Published: 2019

Journal Articles

Iron Deficiency Anemia Caused By Malabsorption from Proton Pump Inhibition

Michael Boxer, MD

Blood (2019) 134 (Supplement_1): 962.

https://doi.org/10.1182/blood-2019-122154

Published: 2019

Journal Articles

Histone 1 Mutations Drive Lymphomagenesis By Inducing Primitive Stem Cell Functions and Epigenetic Instructions through Profound 3D Re-Organization of the B-Cell Genome

Nevin Yusufova, Matthew R Teater, PhD, Alexey Soshnev, Andreas Kloetgen, Adewola Osunsade, Joseph Conway, Ashley Doane, Arthur Skoultchi, Aristotelis Tsirigos, PhD, Yael David, C. David Allis, PhD, Ethel Cesarman, MD PhD, Ari Melnick, MD

Blood (2019) 134 (Supplement_1): 23.

https://doi.org/10.1182/blood-2019-127774

Published: 2019

Journal Articles

Macrophage Hypercellularity Accompanies Erythroid Hyperplasia in Sickle Cell Mice and during Recovery from Blood Loss in Wild Type Mice

Oluwabukola Gbotosho, BSc, MSc, PhD, Maria G Kapetanaki, PhD, Samit Ghosh, Frances Weidert, MS, Grant C. Bullock, MD PhD, Solomon Fiifi Ofori-Acquah, Gregory J Kato, MD

Blood (2019) 134 (Supplement_1): 3528.

https://doi.org/10.1182/blood-2019-127224

Published: 2019

Journal Articles

Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia

Bruno Fattizzo, MD, Marc Michel, Laetitia Languille, Juri Giannotta, MD, Henrik Frederiksen, MD Prof, Francesca Romana Mauro, MD, Bernd Jilma, Elisa Lucchini, MD, Andrea Patriarca, MD, Francesco Zaja, MD, Anita Hill, MD PhD, Sigbjorn Berentsen, MD PhD, Wilma Barcellini

Blood (2019) 134 (Supplement_1): 3516.

https://doi.org/10.1182/blood-2019-125524

Published: 2019

Journal Articles

Computational Systems Biology Models for the Identification of Metabolic Vulnerabilities in Multiple Myeloma

Luis Vitores V. Valcárcel, MSc, Raquel Ordoñez, PhD, Iñigo Apaolaza, MSc, Ana Valcárcel, Leire Garate, Cem Meydan, PhD, Bruno Paiva, PhD, Ari M Melnick, MD, Jesús San-Miguel, Francisco J. Planes, Xabier Agirre, PhD, Felipe Prosper, MD PhD

Blood (2019) 134 (Supplement_1): 3084.

https://doi.org/10.1182/blood-2019-123970

Published: 2019

Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2945.

https://doi.org/10.1182/blood-2019-123836

Published: 2019

Journal Articles

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, Philomena Colucci, DO, MS, Dilan Paranagama, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2948.

https://doi.org/10.1182/blood-2019-124343

Published: 2019

Journal Articles

Endocytosis of the Thrombopoietin Receptor Mpl Regulates Both Megakaryocyte and Erythroid Maturation in Mice

Nathan Eaton, BS, Melissa M. Lee-Sundlov, PhD, Theresa A. Dlugi, PhD, Jon Wieser, BS, Haley E. Ramsey, PhDMSc, Martha Sola-Visner, MD, Karin M. Hoffmeister, MD, Hervé Falet, PhD

Blood (2019) 134 (Supplement_1): 2477.

https://doi.org/10.1182/blood-2019-126820

Published: 2019

Journal Articles

Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models

Blood (2019) 134 (Supplement_1): 2671.

https://doi.org/10.1182/blood-2019-123418

Published: 2019

Journal Articles

CK2 Inhibitor CX4945 Shows Strong In Vivo Synergistic Anti-Leukemia Activity with Rapamycin in B-ALL Due to Enhanced Ikaros Mediated Repression of mTOR Pathway

Chandrika Gowda, MBBS, Chunhua Song, MD, Yali Ding, PhD, Pavan kumar Dhanyamraju, PhD, Soumya Iyer, PhD, Jonathon Payne, Yevgeniya Bamme, MD, Arati Sharma, PhD, Kimberly J. Payne, PhD, Sinisa Dovat, MD PhD

Blood (2019) 134 (Supplement_1): 2634.

https://doi.org/10.1182/blood-2019-131790

Published: 2019

Journal Articles

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

Franck Morschhauser, MD PhD, Herve Tilly, MD PhD, Aristeidis Chaidos, Tycel J. Phillips, MD, Vincent Ribrag, MD, Philip Campbell, MBBS, FRACP, FRCPA, Damaj Gandhi Laurent, MD PhD, Wojciech Jurczak, MD PhD, Pamela McKay, MD, Stephen Opat, John Radford, Jennifer Whalen, Anand Rajarethinam, Susan Benedict Navia, Deyaa Adib, Gilles Salles, MD PhD

Blood (2019) 134 (Supplement_1): 123.

https://doi.org/10.1182/blood-2019-128096

Published: 2019

Journal Articles

High Accuracy, Low-Cost Transcriptional Diagnostic to Transform Lymphoma Care in Low- and Middle-Income Countries

Edward Briercheck, MD, Fabiola Valvert, MD, Elizabeth Solorzano, MSc, Oscar Silva, MD PhD, Maneka Puligandla, MS, Marcos Mauricio Siliézar Tala, MD, Timothy Guyon, MSc, Samuel L. Dixon, BS, Robert Terbrueggen, PhD, Yasodha Natkunam, MD PhD, Kristen E. Stevenson, MS, David M Weinstock

Blood (2019) 134 (Supplement_1): 409.

https://doi.org/10.1182/blood-2019-121397

Published: 2019

Journal Articles

The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models

Alison R. Moliterno, MD, Donna Marie Williams, PhD, Liping Li, MD PhD, Lingling Xian, MD PhD, Li Luo, PhD, Amy S. Duffield, MD PhD, Ophelia Rogers, Jerry L. Spivak, MD, Linda Resar, MD

Blood (2019) 134 (Supplement_1): 472.

https://doi.org/10.1182/blood-2019-131432

Published: 2019

Journal Articles

Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure

Blood (2019) 134 (Supplement_1): 450.

https://doi.org/10.1182/blood-2019-130442

Published: 2019

Journal Articles

Genetic Vulnerabilities of DNMT3A R882H in Myeloid Malignancies

Malgorzata Gozdecka, PhD, Monika Dudek, MSc, Konstantinos Tzelepis, Aristi Damaskou, MSc, Vijay Baskar, PhD, Penny Wright, Graham Duddy, Eshwar Meduri, PhD, Milena Mazan, PhD, Kosuke Yusa, PhD, Brian J. P. Huntly, PhD MRCP, MB, FRCPath, George S. Vassiliou, FRCPath, MRCP, PhD

Blood (2019) 134 (Supplement_1): 111.

https://doi.org/10.1182/blood-2019-126505

Published: 2019

Journal Articles

Elucidating an Erythroblast Survival Mechanism: Differential Contributions of Exosome Complex Catalytic Subunits

Charu Mehta, MS, Isabela J Fraga de Andrade, Bachelors in Biological Science, Nobuyuki Tanimura, PhD, Gary M Wilson, Erik A. Ranheim, MD PhD, Joshua J Coon, PhD, Emery H Bresnick, PhD

Blood (2019) 134 (Supplement_1): 155.

https://doi.org/10.1182/blood-2019-126917

Published: 2019

Journal Articles

EPCR Deficiency Prevents Development of Hemophilic Arthropathy

Jhansi Magisetty, PhD MSc, Usha Pendurthi, PhD, Charles T. Esmon, PhD, L. Vijaya Mohan Rao, PhD

Blood (2019) 134 (Supplement_1): 159.

https://doi.org/10.1182/blood-2019-124972

Published: 2019

Journal Articles

PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71

Justin D. Kaner, MD, Montreh Tavakkoli, MA,MD, Lisa Toudic, Brett M. Stevens, PhD, Craig T Jordan, PhD, Tony Taldone, PhD, Gabriela Chiosis, PhD, Ellen K. Ritchie, MD, Pinkal Desai, MDMPH, Michael B. Samuel, MD, Sangmin Lee, MD, Gail J. Roboz, MD, Monica L. Guzman, PhD

Blood (2019) 134 (Supplement_1): 3935.

https://doi.org/10.1182/blood-2019-128276

Published: 2019

NARROW

GATA2 -Dependent Developmental and Regenerative Networks

PU.1 Enforces Hematopoietic Stem Cell Quiescence during Chronic Inflammation

Iron Deficiency Anemia Caused By Malabsorption from Proton Pump Inhibition

Histone 1 Mutations Drive Lymphomagenesis By Inducing Primitive Stem Cell Functions and Epigenetic Instructions through Profound 3D Re-Organization of the B-Cell Genome

Macrophage Hypercellularity Accompanies Erythroid Hyperplasia in Sickle Cell Mice and during Recovery from Blood Loss in Wild Type Mice

Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia

Computational Systems Biology Models for the Identification of Metabolic Vulnerabilities in Multiple Myeloma

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Endocytosis of the Thrombopoietin Receptor Mpl Regulates Both Megakaryocyte and Erythroid Maturation in Mice

Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models

CK2 Inhibitor CX4945 Shows Strong In Vivo Synergistic Anti-Leukemia Activity with Rapamycin in B-ALL Due to Enhanced Ikaros Mediated Repression of mTOR Pathway

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

High Accuracy, Low-Cost Transcriptional Diagnostic to Transform Lymphoma Care in Low- and Middle-Income Countries

The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models

Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure

Genetic Vulnerabilities of DNMT3A R882H in Myeloid Malignancies

Elucidating an Erythroblast Survival Mechanism: Differential Contributions of Exosome Complex Catalytic Subunits

EPCR Deficiency Prevents Development of Hemophilic Arthropathy

PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only